Pilot Trials With a KLH Conjugated Bivalent Ganglioside Vaccine Mixed With Immunological Adjuvants QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV.

Trial Profile

Pilot Trials With a KLH Conjugated Bivalent Ganglioside Vaccine Mixed With Immunological Adjuvants QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Melanoma vaccine (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 30 Nov 2010 Additional lead trial investigator (Paul Chapman) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top